Beyond Ozempic: The GLP-1 boom
US$ 21.30
surmount-1 tirzepatide obesity nejm 2022 weight loss percent Trial In patients with #obesity, incretin-based
Description
As with other incretin drugs, tirzepatide comes with potential side effects
Transitioning from semaglutide People who switch from semaglutide to tirzepatide after a plateau often experience renewed weight loss
00656-2/asset/ccb5d465-a316-405d-847e-f889e2a34a2c/main.assets/gr3_lrg.jpg)
Patients should be aware of early signs of trouble
Zepbound/Mounjaro is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
